{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:53:21Z","timestamp":1790618001008,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,4]]},"DOI":"10.7759\/cureus.96090","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T17:55:44Z","timestamp":1762278944000},"source":"Crossref","is-referenced-by-count":1,"title":["Immunotherapy in Early Parkinson's Disease: A Biomarker-Driven Trial Framework for Secondary Prevention"],"prefix":"10.7759","author":[{"given":"Roman","family":"Kniazev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-025-00886-4","article-title":"Prasinezumab slows motor progression in Parkinsons disease: beyond the clinical data","volume":"11","author":"Xiao B","year":"2025","unstructured":"Xiao B, Tan EK. Prasinezumab slows motor progression in Parkinsons disease: beyond the clinical data. NPJ Parkinsons Dis. 2025, 11:31. 10.1038\/s41531-025-00886-4","journal-title":"NPJ Parkinsons Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck CH","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, et al.. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023, 388:9-21. 10.1056\/NEJMoa2212948","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.37349\/ent.2023.00048","article-title":"Targeting \u03b1-synuclein aggregation with immunotherapy: a promising therapeutic approach for Parkinson\u2019s disease","volume":"3","author":"Henriquez G","year":"2023","unstructured":"Henriquez G, Narayan M. Targeting \u03b1-synuclein aggregation with immunotherapy: a promising therapeutic approach for Parkinson\u2019s disease. Explor Neuroprot Ther. 2023, 3:207-34. 10.37349\/ent.2023.00048","journal-title":"Explor Neuroprot Ther"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-015-0008-9","article-title":"Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy","volume":"10","author":"Mandler M","year":"2015","unstructured":"Mandler M, Valera E, Rockenstein E, et al.. Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy. Mol Neurodegener. 2015, 10:10. 10.1186\/s13024-015-0008-9","journal-title":"Mol Neurodegener"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12770-x","article-title":"An update on immune-based alpha-synuclein trials in Parkinson's disease","volume":"272","author":"Alfaidi M","year":"2024","unstructured":"Alfaidi M, Barker RA, Kuan WL. An update on immune-based alpha-synuclein trials in Parkinson's disease. J Neurol. 2024, 272:21. 10.1007\/s00415-024-12770-x","journal-title":"J Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30449-X","article-title":"Detection of \u03b1-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study","volume":"20","author":"Iranzo A","year":"2021","unstructured":"Iranzo A, Fairfoul G, Ayudhaya ACN, et al.. Detection of \u03b1-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study. Lancet Neurol. 2021, 20:203-12. 10.1016\/S1474-4422(20)30449-X","journal-title":"Lancet Neurol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29766","article-title":"Detecting misfolded \u03b1-synuclein in blood years before the diagnosis of Parkinson's disease","volume":"39","author":"Kluge A","year":"2024","unstructured":"Kluge A, Schaeffer E, Bunk J, et al.. Detecting misfolded \u03b1-synuclein in blood years before the diagnosis of Parkinson's disease. Mov Disord. 2024, 39:1289-99. 10.1002\/mds.29766","journal-title":"Mov Disord"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.0792","article-title":"Skin biopsy detection of phosphorylated \u03b1-synuclein in patients with synucleinopathies","volume":"331","author":"Gibbons CH","year":"2024","unstructured":"Gibbons CH, Levine T, Adler C, et al.. Skin biopsy detection of phosphorylated \u03b1-synuclein in patients with synucleinopathies. JAMA. 2024, 331:1298-306. 10.1001\/jama.2024.0792","journal-title":"JAMA"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.0985","article-title":"Conversion to Parkinson disease in the PARS hyposmic and dopamine transporter-deficit prodromal cohort","volume":"74","author":"Jennings D","year":"2017","unstructured":"Jennings D, Siderowf A, Stern M, Seibyl J, Eberly S, Oakes D, Marek K. Conversion to Parkinson disease in the PARS hyposmic and dopamine transporter-deficit prodromal cohort. JAMA Neurol. 2017, 74:933-40. 10.1001\/jamaneurol.2017.0985","journal-title":"JAMA Neurol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1148\/rg.230133","article-title":"Practical overview of (123)I-ioflupane imaging in Parkinsonian syndromes","volume":"44","author":"Mercer MK","year":"2024","unstructured":"Mercer MK, Revels JW, Blacklock LC, et al.. Practical overview of (123)I-ioflupane imaging in Parkinsonian syndromes. Radiographics. 2024, 44:e230133. 10.1148\/rg.230133","journal-title":"Radiographics"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz030","article-title":"Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study","volume":"142","author":"Postuma RB","year":"2019","unstructured":"Postuma RB, Iranzo A, Hu M, et al.. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain. 2019, 142:744-59. 10.1093\/brain\/awz030","journal-title":"Brain"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adt7195","article-title":"Alpha-synuclein seed amplification assays: data sharing, standardization needed for clinical use","volume":"11","author":"Lashuel HA","year":"2025","unstructured":"Lashuel HA, Surmeier DJ, Simuni T, et al.. Alpha-synuclein seed amplification assays: data sharing, standardization needed for clinical use. Sci Adv. 2025, 11:eadt7195. 10.1126\/sciadv.adt7195","journal-title":"Sci Adv"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-025-01572-8","article-title":"Exploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumab","volume":"8","author":"Taylor KI","year":"2025","unstructured":"Taylor KI, Lipsmeier F, Scelsi MA, et al.. Exploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumab. NPJ Digit Med. 2025, 8:365. 10.1038\/s41746-025-01572-8","journal-title":"NPJ Digit Med"},{"key":"ref14","unstructured":"A study to evaluate the effects of ACI-7104.056 vaccination in patients with early stages of Parkinson's disease (VacSYn). (2025). Accessed. October 28, 2025: https:\/\/clinicaltrials.gov\/study\/NCT06015841."},{"key":"ref15","unstructured":"AC Immune reports further positive interim results from Phase 2 trial of ACI-7104.056 active immunotherapy in early Parkinson\u2019s disease. (2025). Accessed. October 28, 2025: https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immune-reports-further-positive-interim-results-phase-2...."},{"key":"ref16","unstructured":"Vaxxinity demonstrates target engagement of toxic alpha-synuclein in Parkinson\u2019s patients (UB-312 phase 1). (2024). Accessed. October 28, 2025: https:\/\/www.nasdaq.com\/press-release\/vaxxinity-announces-positive-target-engagement-data-from-phase-1-clinical-trial-for."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-017-0013-5","article-title":"Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson's disease trial","volume":"3","author":"Gendelman HE","year":"2017","unstructured":"Gendelman HE, Zhang Y, Santamaria P, et al.. Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson's disease trial. NPJ Parkinsons Dis. 2017, 3:10. 10.1038\/s41531-017-0013-5","journal-title":"NPJ Parkinsons Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to Alzheimer's disease","volume":"378","author":"Honig LS","year":"2018","unstructured":"Honig LS, Vellas B, Woodward M, et al.. Trial of solanezumab for mild dementia due to Alzheimer's disease. N Engl J Med. 2018, 378:321-30. 10.1056\/NEJMoa1705971","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/426279-immunotherapy-in-early-parkinsons-disease-a-biomarker-driven-trial-framework-for-secondary-prevention","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T17:55:45Z","timestamp":1762278945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/426279-immunotherapy-in-early-parkinsons-disease-a-biomarker-driven-trial-framework-for-secondary-prevention"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.96090","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,4]]}}}